Health Care · Orthopedic, Prosthetic & Surgical Appliances & Supplies

ENOV Enovis CORP SEC Filings & Insider Trading Activity 2026

company
CIK 1420800126 filings
Russell 2000

ENOV at a glance

Enovis CORP (ENOV, SEC CIK 1420800) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Enovis CORP (ENOV) reported revenue of $2.2 billion (up 6.7% from FY2024) and a net loss of $1.2 billion. Diluted EPS was -$20.75.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Enovis CORP (ENOV) shares worth $570.6 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Lalor Angela S on November 13, 2026 of 880 shares at $28.27 per share.
  • In the last 90 days, ENOV insiders reported 13 open-market purchases ($649K) and 0 open-market sales ($0) on Form 4, a net purchase of $649K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$2.2B
+6.7% vs prior year
Insiders · 90 days
13 buys · 0 sells
Net +$649K
13F holders
26 funds
$570.6M · −3 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • Sarbanes-Oxley Act compliance risk from failed internal control integration at acquisitions, e.g., Lima Acquisition, possibly causing material misstatements in financial reports
  • Geopolitical risk from supply chain in China and Asia; political instability risks disrupting access to raw materials critical to manufacturing
  • Manufacturing disruption risk from equipment failure, natural disasters, terrorism, labor shortages affecting facility operations and customer order fulfillment
  • Competitive risk from superior rival technologies and products; competitors with greater resources could cause market share loss and pricing pressure
  • Financial risk of $1.7B+ outstanding debt subject to restrictive covenants limiting transactions and increasing vulnerability to economic downturns

Management Discussion & Analysis

  • Revenue $2.248B, up 5.1% YoY: P&R $1.137B (+$39M), Recon $1.111B (+$101.4M)
  • Operating loss margin worsened: P&R (32.9)% vs (29.3)%, Recon (67.5)% vs (45.0)% in 2024 due to goodwill impairments ($387.8M P&R, $662M Recon)
  • Best segment Recon: Adjusted EBITDA $239.9M (+$23M), margin stable 21.6% vs 21.5%; worst P&R operating loss margin (32.9)%
  • Cash flow: Operating cash flow $217.3M (+$103.8M), CapEx $197.4M, acquisitions $26.9M; Financing used $52.4M including $3.5M buybacks; $36.4M cash on hand
  • Forward outlook: Credit facility increased to $1.1B revolver and $700M term loan; Senior secured leverage ratio covenant of 3.50:1; risks from goodwill impairments and acquisition integration costs

Business Overview

  • Core business model: Orthopedic solutions via two segments; Prevention & Recovery (P&R) and Reconstructive (Recon) with global manufacturing and sales
  • New emphasis on Recon segment growth via $865.6M Lima acquisition in Jan 2024, adding digital innovation and customized hardware
  • Strategic shift: Divested Dr Comfort Footcare Solutions in Oct 2025; focus sharpened on direct sales integration and streamlined global operations
  • Notable metric: Net sales grew 6.7% to $2.248B in 2025, driven by existing business growth and favorable currency, despite $17.3M sales loss from divestitures
  • Unusual fact: Reported $1.05B goodwill impairment charge in 2025, a significant non-cash expense impacting operating loss and net loss margins

AI summary of the ENOV 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Oct 2, 2026

Risk Factors

  • No material changes to risk factors from the 2025 Form 10-K
  • Investment risk: business disruption could harm results, liquidity, and securities value
  • Market risk: investors could lose all or part of their investment

Management Discussion & Analysis

  • Revenue $558.7M, up $9.8M or 1.8% YoY, driven by existing-business growth
  • Gross margin 60.8% vs 59.9% YoY, operating margin 0.6% vs (101.7)%
  • Recon best performer: sales $273.3M, up 6.0%; P&R sales $285.4M, down 1.9%
  • Operating cash flow $170.5M vs $128.7M; capital spending $133.2M and net debt repayments $43.3M
  • eCential acquisition expected in fourth quarter 2026; tariffs, inflation, supply disruptions and geopolitical tensions remain headwinds

AI summary of the ENOV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 results released for the quarter ended October 2, 2026
  • Earnings details and financial metrics available in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q3 sales $558.7M, up 2% reported and 5% organically, with Reconstructive growth 6% and P&R organic growth 3%
  • Adjusted EBITDA $103.5M, margin 18.5%, versus 17.3% a year earlier, signaling improved operating leverage
Filed Sep 1, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Binding offer to acquire eCential Robotics for €155 million upfront enterprise value and approximately €176 million cash consideration
  • Additional contingent consideration of up to €35 million tied to milestone achievement

Item 7.01: Regulation FD Disclosure

  • Proposed acquisition of eCential Robotics, developer of surgical robotics and enabling technologies
  • Enterprise value approximately €155M, with €176M upfront cash consideration
Filed Aug 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 fiscal 2026 results released for quarter ended July 3, 2026
  • Investor conference call scheduled for August 6, 2026 at 8:30 a.m. Eastern

Item EX-99.1: Item EX-99.1

  • Q2 sales $582.8M, up 3% reported and 5% organic, indicating improving underlying demand
  • Reconstructive sales rose 8% reported and 6% organic, offsetting P&R’s 1% reported decline

AI summaries of ENOV 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ENOV

Don't miss the next ENOV filing

  • Alerts as it files. A push when ENOV files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ENOV, by share count.
  • Ask anything. An AI agent that reads every ENOV filing and answers with sources.

ENOV alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Singleton Laura LeeFNov 18, 2026$27.10
Lalor Angela SBuyNov 13, 2026$28.27
Lalor Angela SBuyNov 12, 2026$27.71
Lalor Angela SBuyNov 12, 2026$28.29
Lalor Angela SBuyNov 11, 2026$28.86
Wienbar Sharon LBuyNov 11, 2026$27.76
Wienbar Sharon LBuyNov 10, 2026$28.43
Lalor Angela SBuyNov 10, 2026$28.28

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$2.1B$2.2B
Gross Profit-$1.2B$1.3B
Operating Income--$775.7M-$1.1B
Net Income--$825.5M-$1.2B
Gross Margin-56.0%59.8%
Op. Margin--36.8%-50.0%
Net Margin--39.2%-52.7%
Balance Sheet
Total Assets$4.5B$4.7B$3.8B
Equity$3.4B$2.6B$1.5B
ROE--32.2%-79.5%
Per Share
EPS-$-14.93$-20.75
Cash Flow
Operating CF-$113.5M$217.3M
CapEx-$180.7M$197.4M

Source: XBRL data in Enovis CORP (ENOV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ENOV share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ENOV shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$570.6M
Q2 202629$641.6M
Q1 202632$695.4M
Q4 202529$773.4M
Q3 202530$880.9M
Q2 202527$904.7M
Q1 202524$665.1M
Q4 202421$627.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 218 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ENOV filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
4Nov 16, 2026--
4Nov 12, 2026--
4Nov 12, 2026--
4Nov 10, 2026--
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Oct 1, 2026--
4Sep 8, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
8-KSep 1, 2026Analysis-
SC 13GAug 14, 2026-
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
4Jul 1, 2026--
4Jun 16, 2026--
4Jun 16, 2026--
4Jun 15, 2026--
4Jun 11, 2026--
4May 21, 2026-
4May 21, 2026-
4May 21, 2026-
4May 21, 2026-
4May 21, 2026-

Related Health Care companies

All Health Care →

ENOV SEC filings: frequently asked questions

Are ENOV insiders buying or selling?

In the last 90 days, Enovis CORP (ENOV) officers, directors and 10% owners reported 13 open-market purchases worth $648,927 by 4 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ENOV stock?

As of September 30, 2026, the largest Enovis CORP (ENOV) holders among the 13F filers tracked by SignalX were BlackRock ($188.4 million), Vanguard Portfolio Management LLC ($67.9 million), State Street Corp ($45.7 million), Vanguard Capital Management LLC ($44.8 million), Dimensional Fund Advisors ($42.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ENOV's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Enovis CORP (ENOV) reported revenue of $2.2 billion (up 6.7% from FY2024) and a net loss of $1.2 billion. Diluted EPS was -$20.75. The figures come from the XBRL data in the 10-K.

What are the main risks in ENOV's latest 10-K?

In the 10-K filed February 26, 2026, Enovis CORP (ENOV) flagged: Sarbanes-Oxley Act compliance risk from failed internal control integration at acquisitions, e.g., Lima Acquisition, possibly causing material misstatements in financial reports. Geopolitical risk from supply chain in China and Asia; political instability risks disrupting access to raw materials critical to manufacturing. (AI summary of the Risk Factors section.)

What did ENOV report in its latest 8-K?

Enovis CORP (ENOV) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 results released for the quarter ended October 2, 2026.

What are the latest ENOV SEC filings?

Enovis CORP (ENOV) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 20, 2026.

What is ENOV's SEC CIK number?

Enovis CORP (ENOV)'s SEC Central Index Key (CIK) is 1420800. EDGAR lists every ENOV filing under that number.

Ask anything about ENOV

The research agent reads ENOV's filings, financials, insider trades and 13F holders, then answers with sources.